Fibroadipogenic progenitor-derived exosomes for regeneration of dystrophic muscles
AssigneeExofix S.R.L.
InventorsMartina SANDONA', Silvia CONSALVI, Valentina SACCONE
Life of this patent
Estimating the term…
Abstract
The present invention refers to exosomes obtained from fibro-adipogenic progenitors (FAPs) previously exposed to histone deacetylase (HDAC) inhibitors. It also relatesto such exosomes for the use in the treatment of muscular dystrophies, in particular in the treatment of Duchenne Muscular Dystrophy. Pharmaceutical compositions comprising such exosomes and their medical uses are also within the scope of the present invention.
Claims15
Isolated extracellular vesicles containing at least one miRNA selected from the group consisting of:
- miR-206-3p, miR-542-5p, miR-449a-5p, miR-342-3p, miR-320-3p, miR-192-5p, miR-423-5p, miR-376a-3p, miR-145a-5p, miR-224-5p, miR-30a-5p, miR-494a-3p, miR-29a-3p and miR-7b-5p
- obtained by the process comprising:
- a) culturing fibro-adipogenic progenitor cells;
- b) exposing, in vivo or ex-vivo, the cells as obtained in step a) to HDAC inhibitors;
- c) culturing the cells as obtained in step b) to confluence;
- and
- d) isolating extracellular vesicles form the cells as obtained in step c).
Method for the preparation of pharmacologically modulated isolated extracellular vesicles containing at least one miRNA selected from the group consisting of:
- miR-206-3p, miR-542-5p, miR-449a-5p, miR-342-3p, miR-320-3p, miR-192-5p, miR-423-5p, miR-376a-3p, miR-145a-5p, miR-224-5p, miR-30a-5p, miR-494-3p, miR-29a-3p and miR-7b-5p which are able to stimulate the regeneration of dystrophic muscle, the method comprising:
- a) culturing fibro-adipogenic progenitor cells
- b) exposing, in vivo or ex-vivo, the cells as obtained in step a) to HDAC inhibitors
- c) culturing the cells as obtained in step b) to confluence
- d) isolating extracellular vesicles form the cells as obtained in step c).
Dependencies are inferred from the claim text.